Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease

Figure 1 Clinical activity in inflammatory bowel disease patients at 8-weeks prior, time of switch, and weeks 12 and 24 following biosimilar switching.

Figure 2 Probability of remaining on biosimilar ustekinumab after switching from the originator among all patients with inflammatory bowel disease and patients with ulcerative colitis or Crohn’s disease. A: Patients with inflammatory bowel disease; B: Patients with ulcerative colitis or Crohn’s disease. UC: Ulcerative colitis; CD: Crohn’s disease.